| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| MAdCAM-1 | HOTAvitag MAM-H8251 | Biotinylated Human MAdCAM-1 Protein, Fc,Avitag™ (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| MAdCAM-1 | Human MAdCAM-1 Protein, Fc Tag, low endotoxin (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $355.00 100ug | ||
| MAdCAM-1 | Human MAdCAM-1 Protein, His Tag, low endotoxin (MALS & SPR verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $415.00 100ug | ||
| MAdCAM-1 | Cynomolgus MAdCAM-1 Protein, His Tag, low endotoxin | Cynomolgus | HEK293 | ![]() | SDS-PAGE | $355.00 100ug | ||
| MAdCAM-1 | Avitag MAM-C82E3 | Biotinylated Cynomolgus MAdCAM-1 Protein, His,Avitag™ (MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $350.00 25ug | |
| MAdCAM-1 | Mouse MAdCAM-1 Protein, His Tag, low endotoxin (MALS & SPR verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $355.00 100ug | ||
| MAdCAM-1 | Avitag MAM-M82E3 | Biotinylated Mouse MAdCAM-1 Protein, His,Avitag™ (MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $350.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ontamalimab | SHP-647; PF-00547659; PF-547659 | Phase 3 Clinical | Pfizer Inc | Colitis, Ulcerative; Crohn Disease; Fatty Liver; Ileitis | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Colitis, Ulcerative; Crohn Disease; Pouchitis | Details |
| Vedolizumab Biosimilar (Intas Pharmaceuticals) | INTP-53; INTP53 | Phase 3 Clinical | Intas Pharmaceuticals Ltd | Colitis, Ulcerative | Details |
| Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 1 Clinical | Alvotech Swiss Ag | Colitis, Ulcerative; Immune System Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Carcinoma, Non-Small-Cell Lung; Celiac Disease; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Crohn Disease; Gastritis; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Inflammatory Bowel Diseases; Melanoma; Neoplasms; Pediatric Crohn's disease; Pediatric ulcerative colitis; Pouchitis; Solid tumours; Urogenital Neoplasms | Details |